Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (Review)

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 3-12

  Jiang, Jue ^a   Jiang, Hong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; Cognitive deficits; Desflurane; Isoflurane; Sevoflurane; Tau; amyloid protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DESFLURANE; ISOFLURANE; SEVOFLURANE; TAU PROTEIN; CASPASE; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT;

ALLELE; ALZHEIMER DISEASE; AMNESIA; CALCIUM HOMEOSTASIS; EXTRACELLULAR SPACE; HUMAN; LONG TERM POTENTIATION; MEMORY; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SPATIAL LEARNING; ANALOGS AND DERIVATIVES; COGNITION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANESTHETICS, INHALATION; CASPASES; COGNITION; HUMANS; ISOFLURANE; METHYL ETHERS; TAU PROTEINS;

EID: 84926669043     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3424     Document Type: Review

References (106)

1. Alzheimer's Association: Alzheimer's disease facts and figures. Alzhemier's Dement 7: 208-244, 2011.
2. Brookmeyer R, Johnson E, Ziegler-Graham K and Arrighi HM: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3: 186-191, 2007.
3. Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G and Tanzi RE: The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 104: 988-994, 2006.
4. Planel E, Bretteville A, Liu L, Virag L, Du AL, Yu WH, Dickson DW, Whittington RA and Duff KE: Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J 23: 2595-2604, 2009.
5. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM and Eckenhoff MF: Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 101: 703-709. 2004.
6. Le Freche H, Brouillette J, Fernandez-Gomez FJ, et al: Tau phosphorylation and sevoflurane anesthesia: An association to postoperative cognitive impairment. Anesthesiology 116: 779-787, 2012.
7. Run X, Liang Z, Zhang L, Iqbal K, Grundke-Iqbal I and Gong CX: Anesthesia induces phosphorylation of tau. J Alzheimers Dis 16: 619-626, 2009.
8. Tan W, Cao X, Wang J, Lv H, Wu B and Ma H: Tau hyperphosphorylation is associated with memory impairment after exposure to 1.5% isoflurane without temperature maintenance in rats. Eur J Anaesthesiol 27: 835-841, 2010.
9. Xie Z and Tanzi RE: Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol 41: 346-359, 2006.
10. Tang JX, Baranov D, Hammond M, Shaw LM, Eckenhoff MF and Eckenhoff RG: Human Alzheimer and inflammation biomarkers after anesthesia and surgery. Anesthesiology 115: 727-732, 2011.
11. Gasparini M, Vanacore N, Schiaffini C, Brusa L, Panella M, Talarico G, Bruno G, Meco G and Lenzi GL: A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci 23: 11-14, 2002.
12. Knopman DS, Petersen RC, Cha RH, Edland SD and Rocca WA: Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology 65: 986-990, 2005.
13. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS and Wisniewski HM: Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089, 1986.
14. Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
15. Iqbal K and Grundke-Iqbal I: Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12: 38-55, 2008.
16. Trojanowski JQ and Lee VM: Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol 144: 449-453, 1994.
17. Xie Z and Xu Z: General anesthetics and β-amyloid protein. Prog Neuropsychopharmacol Biol Psychiatry 47: 140-146, 2013.
18. Gu Y, Misonou H, Sato T, Dohmae N, Takio K and Ihara Y: Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J Biol Chem 276: 35235-35238, 2001.
19. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB and Haass C: Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835-841, 2001.
20. Yu C, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R and Sisodia SS: Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 276: 43756-43760, 2001.
21. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG and Love S: Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18: 240-252, 2008.
22. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL and Martins RN: Clearance mechanisms of Alzheimer's amyloid-beta peptide: Implications for therapeutic design and diagnostic tests. Mol Psychiatry 14: 469-486, 2009.
23. Eckman EA and Eckman CB: Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33: 1101-1105, 2005.
24. Higuchi M, Iwata N and Saido TC: Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions. Biochim Biophys Acta 1751: 60-67, 2005.
25. Wang DS, Dickson DW and Malter JS: beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006: 58406, 2006.
26. Turner AJ and Tanzawa K: Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11: 355-364, 1997.
27. Turner AJ, Isaac RE and Coates D: The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 23: 261-269, 2001.
28. Kanemitsu H, Tomiyama T and Mori H: Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350: 113-116, 2003.
29. Ho L, Qin W, Pompl PN, et al: Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904, 2004.
30. Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, Kervinen K, Kesäniemi YA, Riekkinen PJ and Laakso M: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 315: 1045-1049, 1997.
31. Edland SD, Wavrant-De Vriesé F, Compton D, Smith GE, Ivnik R, Boeve BF, Tangalos EG and Petersen RC: Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: Evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 345: 21-24, 2003.
32. Raber J, Huang Y and Ashford JW: ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25: 641-650, 2004.
33. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS and Craft S: Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162: 313-319, 2003.
34. Ashe KH and Zahs KR: Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645, 2010.
35. Sakono M and Zako T: Amyloid oligomers: Formation and toxicity of Abeta oligomers. FEBS J 277: 1348-1358, 2010.
36. Caughey B and Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-298, 2003.
37. Haass C and Selkoe DJ: Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112, 2007.
38. LaFerla FM, Green KN and Oddo S: Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499-509, 2007.
39. Klein WL, Krafft GA and Finch CE: Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224, 2001.
40. Chiti F and Dobson CM: Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366, 2006.
41. Ferreira ST, Vieira MN and De Felice FG: Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345, 2007.
42. Binder LI, Frankfurter A and Rebhun LI: The distribution of tau in the mammalian central nervous system. J Cell Biol 101: 1371-1378, 1985.
43. Buée L, Bussière T, Buée-Scherrer V, Delacourte A and Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130, 2000.
44. Sergeant N, Bretteville A, Hamdane M, et al: Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 5: 207-224, 2008.
45. Ittner LM, Ke YD, Delerue F, et al: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397, 2010.
46. Sultan A, Nesslany F, Violet M, et al: Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286: 4566-4575, 2011.
47. Buée L, Troquier L, Burnouf S, et al: From tau phosphorylation to tau aggregation: What about neuronal death? Biochem Soc Trans 38: 967-972, 2010.
48. Iqbal K, Liu F, Gong CX and Grundke-Iqbal I: Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7: 656-664, 2010.
49. Braak H and Braak E: Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16: 271-284, 1995.
50. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H and Lipton RB: Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20: 573-579, 1999.
51. Van der Jeugd A, Ahmed T, Burnouf S, et al: Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem 95: 296-304, 2011.
52. Polydoro M, Acker CM, Duff K, Castillo PE and Davies P: Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29: 10741-10749, 2009.
53. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N and Takashima A: Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J 26: 5143-5152, 2007.
54. Maccioni RB, Otth C, Concha II and Muñoz JP: The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 268: 1518-1527, 2001.
55. Tatebayashi Y, Planel E, Chui DH, et al: c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J 20: 762-764, 2006.
56. Feinstein SC and Wilson L: Inability of tau to properly regulate neuronal microtubule dynamics: A loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta 1739: 268-279, 2005.
57. Mandelkow EM, Stamer K, Vogel R, Thies E and Mandelkow E: Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24: 1079-1085, 2003.
58. Trojanowski JQLV and Lee VM: Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol 144: 449-453, 1994.
59. Terry RD: The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55: 1023-1025, 1996.
60. Guillozet AL, Weintraub S, Mash DC and Mesulam MM: Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60: 729-736, 2003.
61. Small SA and Duff K: Linking Abeta and tau in late-onset Alzheimer's disease: A dual pathway hypothesis. Neuron 60: 534-542, 2008.
62. Hardy J and Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
63. Tanzi RE and Bertram L: Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120: 545-555, 2005.
64. Jin M, Shepardson N, Yang T, Chen G, Walsh D and Selkoe DJ: Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 108: 5819-5824, 2011.
65. Ma QL, Yang F, Rosario ER, et al: β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29: 9078-9089, 2009.
66. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y and LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421, 2003.
67. Bertram L and Tanzi RE: Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci 9: 768-778, 2008.
68. Liang G, Wang Q, Li Y, Kang B, Eckenhoff MF, Eckenhoff RG and Wei H: A presenilin-1 mutation renders neurons vulnerable to isoflurane toxicity. Anesth Analg 106: 492-500, 2008.
69. Filali M, Lalonde R, Theriault P, Julien C, Calon F and Planel E: Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav Brain Res 234: 334-342, 2012.
70. Perucho J, Rubio I, Casarejos MJ, Gomez A, Rodriguez-Navarro JA, Solano RM, De Yébenes JG and Mena MA: Anesthesia with isoflurane increases amyloid pathology in mice models of Alzheimer's disease. J Alzheimers Dis 19: 1245-1257, 2010.
71. Lu Y, Wu X, Dong Y, Xu Z, Zhang Y and Xie Z: Anesthetic sevoflurane causes neurotoxicity differently in neonatal naïve and Alzheimer disease transgenic mice. Anesthesiology 112: 1404-1416, 2010.
72. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K and Brookes AJ: Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 22: 363-371, 2003.
73. Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, Graff-Radford N and Younkin SG: Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 23: 334-342, 2004.
74. Xie Z, Dong Y, Maeda U, Moir RD, Xia W, Culley DJ, Crosby G and Tanzi RE: The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci 27: 1247-1254, 2007.
75. Xie Z, Dong Y, Maeda U, Moir R, Inouye SK, Culley DJ, Crosby G and Tanzi RE: Isoflurane-induced apoptosis: A potential pathogenic link between delirium and dementia. J Gerontol A Biol Sci Med Sci 61: 1300-1306, 2006.
76. Xie Z, Culley DJ, Dong Y, Zhang G, Zhang B, Moir RD, Frosch MP, Crosby G and Tanzi RE: The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol 64: 618-627, 2008.
77. Zhang B, Tian M, Zheng H, Zhen Y, Yue Y, Li T, Li S, Marcantonio ER and Xie Z: Effects of anesthetic isoflurane and desflurane on human cerebrospinal fluid Aβ and t level. Anesthesiology 119: 52-60, 2013.
78. Dong Y, Xu Z, Zhang Y, McAuliffe S, Wang H, Shen X, Yue Y and Xie Z: RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation. Med Gas Res 1: 5, 2011.
79. Zhen Y, Dong Y, Wu X, Xu Z, Lu Y, Zhang Y, Norton D, Tian M, Li S and Xie Z: Nitrous oxide plus isoflurane induces apoptosis and increases β -amyloid protein levels. Anesthesiology 111: 741-752, 2009.
80. Su D, Zhao Y, Xu H, Wang B, Chen X, Chen J and Wang X: Isoflurane exposure during mid-adulthood attenuates age-related spatial memory impairment in APP/PS1 transgenic mice. PLoS One 7: e50172, 2012.
81. Dong Y, Zhang G, Zhang B, Moir RD, Xia W, Marcantonio ER, Culley DJ, Crosby G, Tanzi RE and Xie Z: The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol 66: 620-631, 2009.
82. Callaway JK, Jones NC, Royse AG and Royse CF: Sevoflurane anesthesia does not impair acquisition learning or memory in the Morris water maze in young adult and aged rats. Anesthesiology 117: 1091-1101, 2012.
83. Chen CW, Lin WY, Chen KB, Wu YS, Kuo YC, Liu HP and Li CY: Inhalational anesthetic sevoflurane rescues retina function in Alzheimer's disease transgenic Drosophila. Curr Alzheimer Res 10: 1005-1014, 2013.
84. Zhang B, Dong Y, Zhang G, et al: The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta-protein levels under hypoxic conditions. J Biol Chem 283: 11866-11875, 2008.
85. Loop T, Dovi-Akue D, Frick M, et al: Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology 102: 1147-1157, 2005.
86. Yu Y and Zhang Y: Desflurane accelerates neuronal cytotoxicity of Aβ by downregulating miR-214. Neurosci Lett 554: 28-33, 2013.
87. Culley DJ, Baxter MG, Yukhananov R and Crosby G: Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology 100: 309-314, 2004.
88. Kvolik S, Glavas-Obrovac L, Bares V and Karner I: Effects of inhaled anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci 77: 2369-2383, 2005.
89. Wei H, Kang B, Wei W, Liang G, Meng QC, Li Y and Eckenhoff G: Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res 1037: 139-147, 2005.
90. Matsuoka H, Kurosawa S, Horinouchi T, Kato M and Hashimoto Y: Inhaled anesthetics induce apoptosis in normal peripheral lymphocytes in vitro. Anesthesiology 95: 1467-1472, 2001.
91. Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, et al: Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain. Anesthesiology 112: 834-841, 2010.
92. Wei H, Liang G, Yang H, Wang Q, Hawkins B, Madesh M, Wang S and Eckenhoff RG: The common inhalational anesthetic isoflurane induces apoptosis via activation of inositol 1,4,5-trisphosphate receptors. Anesthesiology 108: 251-260, 2008.
93. Zhang G, Dong Y, Zhang B, Ichinose F, Wu X, Culley DJ, Crosby G, Tanzi RE and Xie Z: Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. J Neurosci 28: 4551-4560, 2008.
94. Zhang G, Dong Y, Zhang B, Ichinose F, Wu X, Culley DJ, Crosby G, Tanzi RE and Xie Z: Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. J Neurosci 28: 4551-4560, 2008.
95. Zhang Y, Xu Z, Wang H, Dong Y, Shi HN, Culley DJ, Crosby G, Marcantonio ER, Tanzi RE and Xie Z: Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol 71: 687-698, 2012.
96. Zhang Y, Dong Y, Wu X, Lu Y, Xu Z, Knapp A, Yue Y, Xu T and Xie Z: The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem 285: 4025-4037, 2010.
97. Tang JX, Mardini F, Caltagarone BM, Garrity ST, Li RQ, Bianchi SL, Gomes O, Laferla FM, Eckenhoff RG and Eckenhoff MF: Anesthesia in presymptomatic Alzheimer's disease: A study using the triple-transgenic mouse model. Alzheimers Dement 7: 521-531.e1, 2011.
98. Dong Y, Wu X, Xu Z, Zhang Y and Xie Z: Anesthetic isoflurane increases phosphorylated tau levels mediated by caspase activation and Aβ generation. PLoS One 7: e39386, 2012.
99. Planel E, Richter KE, Nolan CE, et al: Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27: 3090-3097, 2007.
100. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y and Takashima A: Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci 24: 2401-2411, 2004.
101. Holtzman A and Simon EW: Body temperature as a risk factor for Alzheimer's disease. Med Hypotheses 55: 440-444, 2000.
102. Liu W, Xu J, Wang H, et al: Isoflurane-induced spatial memory impairment by a mechanism independent of amyloid-beta levels and tau protein phosphorylation changes in aged rats. Neurol Res 34: 3-10, 2012.
103. Menuet C, Borghgraef P, Voituron N, Gestreau C, Gielis L, Devijver H, Dutschmann M, Van Leuven F and Hilaire G: Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: Possible implication for neurodegenerative diseases. Neurobiol Dis 46: 234-243, 2012.
104. Zhang B, Tian M, Zhen Y, Yue Y, Sherman J, Zheng H, Li S, Tanzi RE, Marcantonio ER and Xie Z: The effects of isoflurane and desflurane on cognitive function in humans. Anesth Analg 114: 410-415, 2012.
105. Bianchi SL, Tran T, Liu C, Lin S, Li Y, Keller JM, Eckenhoff RG and Eckenhoff MF: Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics. Neurobiol Aging 29: 1002-1010, 2008.
106. Wan Y, Xu J, Meng F, et al: Cognitive decline following major surgery is associated with gliosis, β-amyloid accumulation, and t phosphorylation in old mice. Crit Care Med 38: 2190-2198, 2010.